About Sanofi SA (EPA:SAN)
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: EPA:SAN
- CUSIP: N/A
- Web: en.sanofi.com
- 50 Day Moving Avg: €26.11
- 200 Day Moving Avg: €26.02
- Trailing P/E Ratio: 11.70
- P/E Growth: 2.33
Frequently Asked Questions for Sanofi SA (EPA:SAN)
What is Sanofi SA's stock symbol?
Sanofi SA trades on the EPA under the ticker symbol "SAN."
Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?
16 analysts have issued 12 month price targets for Sanofi SA's stock. Their predictions range from €75.00 to €100.00. On average, they expect Sanofi SA's stock price to reach €88.50 in the next twelve months. View Analyst Ratings for Sanofi SA.
Who are some of Sanofi SA's key competitors?
Some companies that are related to Sanofi SA include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), VCA (WOOF), NMC Health PLC (NMC), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), Alere (ALR), ConvaTec Group PLC (CTEC) and WuXi PharmaTech (Cayman) (WX).
Who are Sanofi SA's key executives?
MarketBeat Community Rating for Sanofi SA (EPA SAN)MarketBeat's community ratings are surveys of what our community members think about Sanofi SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sanofi SA's management team includes the folowing people:
- Serge Weinberg, Independent Chairman of the Board
- Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
- Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee
- Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee
- Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee
- Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee
- Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee
- David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
- Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee
- Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee
Consensus Ratings for Sanofi SA (EPA:SAN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 10 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.25)|
|Consensus Price Target: ||€88.50|Consensus Price Target History for Sanofi SA (EPA:SAN)
Analysts' Ratings History for Sanofi SA (EPA:SAN)
(Data available from 10/19/2015 forward)
|10/18/2017||Deutsche Bank AG||Set Price Target||Buy||€96.00|
|10/17/2017||Goldman Sachs Group, Inc. (The)||Set Price Target||Neutral||€82.00|
|10/16/2017||Jefferies Group LLC||Set Price Target||Neutral||€90.00|
|10/6/2017||Citigroup Inc.||Set Price Target||Neutral||€88.00|
|10/6/2017||Morgan Stanley||Set Price Target||Buy||€92.00|
|9/14/2017||J P Morgan Chase & Co||Set Price Target||Neutral||€85.00|
|9/12/2017||HSBC Holdings plc||Set Price Target||Neutral||€81.00|
|9/12/2017||BNP Paribas||Set Price Target||Neutral||€85.00|
|9/7/2017||Kepler Capital Markets||Set Price Target||Buy||€90.00|
|7/31/2017||Sanford C. Bernstein||Set Price Target||Neutral||€90.00|
|7/31/2017||Berenberg Bank||Set Price Target||Neutral||€97.00|
|7/31/2017||S&P Global||Set Price Target||Neutral||€90.00|
|7/4/2017||Credit Suisse Group||Set Price Target||Buy||€95.00|
|5/8/2017||Barclays PLC||Set Price Target||Sell||€75.00|
|3/23/2017||Societe Generale||Set Price Target||Buy||€100.00|
|12/6/2016||S&P Global Inc.||Set Price Target||Neutral||€80.00|
|6/30/2016||Independent Research GmbH||Set Price Target||Neutral||€77.00|
|6/9/2016||Baader Bank||Set Price Target||Neutral||€78.00|
|2/9/2016||S&P Equity Research||Set Price Target||Buy||€85.00|
Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Sanofi SA (EPA:SAN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Sanofi SA (EPA:SAN)
Latest Headlines for Sanofi SA (EPA:SAN)